Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PM5PP2PP3PP5_Very_Strong
The NM_002880.4(RAF1):c.788T>C(p.Val263Ala) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V263G) has been classified as Likely pathogenic.
RAF1 (HGNC:9829): (Raf-1 proto-oncogene, serine/threonine kinase) This gene is the cellular homolog of viral raf gene (v-raf). The encoded protein is a MAP kinase kinase kinase (MAP3K), which functions downstream of the Ras family of membrane associated GTPases to which it binds directly. Once activated, the cellular RAF1 protein can phosphorylate to activate the dual specificity protein kinases MEK1 and MEK2, which in turn phosphorylate to activate the serine/threonine specific protein kinases, ERK1 and ERK2. Activated ERKs are pleiotropic effectors of cell physiology and play an important role in the control of gene expression involved in the cell division cycle, apoptosis, cell differentiation and cell migration. Mutations in this gene are associated with Noonan syndrome 5 and LEOPARD syndrome 2. [provided by RefSeq, Jul 2008]
Verdict is Pathogenic. Variant got 16 ACMG points.
PM1
?
PM1 - Located in a mutational hot spot and/or critical and well-established functional domain (e.g., active site of an enzyme) without benign variation
In a hotspot region, there are 9 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 7 uncertain in NM_002880.4
PM2
?
PM2 - Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium
Very rare variant in population databases, with high coverage;
PM5
?
PM5 - Novel missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before
Other missense variant is known to change same aminoacid residue: Variant chr3-12604182-A-C is described in ClinVar as [Likely_pathogenic]. Clinvar id is 40607.Status of the report is reviewed_by_expert_panel, 3 stars.
PP2
?
PP2 - Missense variant in a gene that has a low rate of benign missense variation and in which missense variants are a common mechanism of disease
Missense variant where missense usually causes diseases, RAF1
PP3
?
PP3 - Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.)
MetaRNN computational evidence supports a deleterious effect, 0.817
PP5
?
PP5 - Reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation
Variant 3-12604182-A-G is Pathogenic according to our data. Variant chr3-12604182-A-G is described in ClinVar as [Likely_pathogenic]. Clinvar id is 40608.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Published functional studies demonstrate a damaging effect with increased kinase and phosphorylation of the MEK/ERK pathway (Razzaque et al., 2007; Molzan et al., 2010; Dhandapany et al., 2014); Not observed at significant frequency in large population cohorts (gnomAD); Missense variants in this gene are often considered pathogenic (HGMD); This variant is associated with the following publications: (PMID: 24803665, 29271604, 20679480, 24777450, 22821648, 33300679, 29493581, 17603482, 24957944, 9689060, 15520807, 19020799, 17603483) -
Noonan syndrome Pathogenic:1
Likely pathogenic, no assertion criteria provided
literature only
Database of Curated Mutations (DoCM)
May 13, 2016
- -
Hereditary breast ovarian cancer syndrome Pathogenic:1
Likely pathogenic, criteria provided, single submitter
clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Mar 11, 2024
Variant summary: NBN c.788T>C (p.Phe263Ser) results in a non-conservative amino acid change located in the Nibrin, second BRCT domain of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00019 in 282702 control chromosomes, predominantly at a frequency of 0.0021 within the African or African-American subpopulation in the gnomAD database. The observed variant frequency within African or African-American control individuals in the gnomAD database is approximately 16.8 fold of the estimated maximal expected allele frequency for a pathogenic variant in NBN causing Hereditary Breast and Ovarian Cancer phenotype (0.00013), strongly suggesting that the variant is a benign polymorphism found primarily in populations of African or African-American origin. c.788T>C has been reported in the literature in individuals affected with Hereditary Breast and Ovarian Cancer. These report(s) do not provide unequivocal conclusions about association of the variant with Hereditary Breast and Ovarian Cancer. Co-occurrences with other pathogenic variant(s) have been reported (BRCA2 c.2808_2811delACAA, p.Ala938fsX21), providing supporting evidence for a benign role. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Eight clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Multiple laboratories reported the variant with conflicting assessments. Based on the evidence outlined above, the variant was classified as likely benign. -
Cardiovascular phenotype Pathogenic:1
Likely pathogenic, criteria provided, single submitter
clinical testing
Ambry Genetics
Jun 07, 2019
The p.V263A variant (also known as c.788T>C), located in coding exon 6 of the RAF1 gene, results from a T to C substitution at nucleotide position 788. The valine at codon 263 is replaced by alanine, an amino acid with similar properties, and occurs in the conserved region 2 domain. This variant has been detected in an individual reported to have Noonan syndrome with hypertrophic cardiomyopathy (Razzaque MA et al. Nat. Genet., 2007 Aug;39:1013-7). In vitro functional studies have indicated that this variant results in increased kinase activity, increased phosphorylation of downstream effectors, and increased activation of the MAPK pathway (Razzaque MA et al. Nat. Genet., 2007 Aug;39:1013-7; Molzan M et al. Mol. Cell. Biol., 2010 Oct;30:4698-711; Dhandapany PS et al. Nat. Genet., 2014 Jun;46:635-639). Another variant affecting this codon was reported to occur de novo in a case with hypoplastic left heart syndrome considered associated with Noonan syndrome (Schulz S et al. Prenat. Diagn., 2012 Oct;32:1016-8). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. -
RASopathy Pathogenic:1
Pathogenic, criteria provided, single submitter
clinical testing
Invitae
Jan 29, 2024
This sequence change replaces valine, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 263 of the RAF1 protein (p.Val263Ala). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with clinical features of RAF1-related conditions (PMID: 17603482; Invitae). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 40608). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt RAF1 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects RAF1 function (PMID: 17603482, 20679480, 24777450). This variant disrupts the p.Val263 amino acid residue in RAF1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 22821648). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. -
Noonan syndrome 5 Pathogenic:1
Likely pathogenic, criteria provided, single submitter
clinical testing
Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein